Artal Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Artal Group’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-700,000	Closed	-$14.1M	–	159
2021 Q3	$14.1M	Sell	700,000 -100,000	-13%	-$2.76M	0.32%	68
2021 Q2	$29.9M	Hold	800,000	–	–	0.61%	38
2021 Q1	$20.5M	Buy	+800,000	New	+$20.4M	0.36%	63
2020 Q1	–	Sell	-500,000	Closed	-$11M	–	121
2019 Q4	$11M	Sell	500,000 -500,000	-50%	-$10.1M	0.43%	41
2019 Q3	$14.4M	Hold	1,000,000	–	–	0.58%	37
2019 Q2	$15.8M	Buy	1,000,000 +20,725	+2%	+$282K	0.64%	35
2019 Q1	$14.3M	Buy	979,275 +454,275	+87%	+$5.22M	0.59%	39
2018 Q4	$5.61M	Buy	525,000 +100,000	+24%	+$1.32M	0.21%	67
2018 Q3	$6.49M	Hold	425,000	–	–	0.17%	66
2018 Q2	$5.21M	Hold	425,000	–	–	0.11%	66
2018 Q1	$4.06M	Buy	+425,000	New	+$4.58M	0.05%	80

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Artal Group's DRNA Position: Q4 2021 in Review

Artal Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 700,000 shares — an estimated $14.1M sold.

Artal Group first reported a position in DRNA in Q1 2018 and held it in 11 quarters. The position peaked at $29.9M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Artal Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Artal Group sold 700,000 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $14.1M.
Artal Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 11 quarters.
Artal Group's Dicerna Pharmaceuticals, Inc. position peaked at $29.9M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Artal Group's 13F filing for Q4 2021, filed 11 Feb 2022.